Tanabe Seiyaku, Centocor Revise Licensing Agreement on Remicade

Tanabe Seiyaku has signed an addendum to its licensing agreement with Centocor of Pennsylvania for Remicade, an anti-TNF-alpha monoclonal antibody preparation developed by Centocor. Currently, Tanabe Seiyaku is marketing Remicade for two indications, Crohn's disease and rheumatoid arthritis, and has filed application for use for Behcet's disease. Under the terms of the revised agreement, Tanabe Seiyaku is granted the exclusive rights to develop and market Remicade for all indications including ankylosing spondylitis, psoriasis and ulcerative colitis.
Japan Corporate News